Mumbai, 13 November (Udaipur Kiran)। Shares of Lupin edged higher on Thursday after the company announced it has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Chhatrapati Sambhajinagar (Aurangabad) facility.
The EIR follows a product-specific Pre-Approval Inspection (PAI) conducted by the USFDA between September 1–5, 2025.
Lupin’s stock opened at ₹2,055.80 and was trading at ₹2,055.60, up ₹19.75 or 0.97% from the previous close. The scrip hit an intraday high of ₹2,055.80 and a low of ₹2,033.15, with over 12,500 shares traded on the BSE. The company’s market capitalisation currently stands at ₹93,647.67 crore.
Over the last 52 weeks, the stock has moved between ₹2,403.45 and ₹1,774.00. Promoters hold 46.90%, while institutions and non-institutions own 47.06% and 6.06% respectively.
Lupin is a global, innovation-driven pharmaceutical company engaged in developing and marketing branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across major markets worldwide.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
